kardio.az

Atrial Fibrillation Treatment

Dr. Kənan Əhmədov2 dəq oxu
Atrial Fibrillation Treatment

Atrial fibrillation management has moved a long way from “rate or rhythm”. The 2023 ACC/AHA/ACCP/HRS guideline reframes AF as a staged disease and puts risk factor modification alongside anticoagulation and symptom control rather than after them. The review below summarises that approach on a single page.

Staging

AF is now described in four stages: at risk (risk factors present), pre-AF (structural or electrical predisposition), clinical AF — subdivided into paroxysmal, persistent, long-standing persistent and successfully ablated — and permanent AF, where patient and clinician agree to stop attempting rhythm restoration. Staging matters because the intervention that helps most differs by stage.

Anticoagulation

Stroke risk is assessed with CHA₂DS₂-VASc and bleeding risk with HAS-BLED. DOACs are generally preferred over warfarin: better safety profile, fewer interactions, no routine monitoring. Warfarin remains the agent of choice in moderate-to-severe rheumatic mitral stenosis, in mechanical heart valves, and in end-stage chronic kidney disease or dialysis. Where warfarin is used, the goal is an INR of 2.0 to 3.0 with time in therapeutic range above 70 percent.

The guideline also notes that CHA₂DS₂-VASc, while the best validated score, is not the only option — newer scores such as ATRIA and GARFIELD-AF may perform better in some populations, and recommendations are increasingly framed around annual thromboembolic risk percentage rather than the score alone.

Rate versus rhythm

There is no significant mortality difference between the two strategies, but rhythm control is associated with higher hospitalisation risk, and rate control does not correct AF while rhythm control can prevent progression. Early rhythm control — within a year of diagnosis — reduces hospitalisation and stroke. Younger patients, shorter AF history, higher symptom burden, difficulty achieving rate control, a smaller left atrium, and left ventricular dysfunction or AV regurgitation all favour a rhythm strategy.

For rate control, beta blockers and non-dihydropyridine calcium channel blockers are first line, with digoxin second line and often combined; amiodarone is reserved for acute control when other agents are inappropriate. For cardioversion, anticoagulation is recommended for at least three weeks before and four weeks after if AF has lasted 48 hours or more, or imaging is used to exclude intracardiac thrombus.

Based on the 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation and the 2018 CHEST guideline on antithrombotic therapy for AF.

Atrial fibrillation pharmacotherapy review — AF stages, CHA2DS2-VASc and HAS-BLED scoring, rate versus rhythm control, per the 2023 ACC/AHA/ACCP/HRS guideline

Şərhlər

İlk şərhi siz yazın

Şərh yazın

Şərhlər dərc olunmazdan əvvəl yoxlanılır. E-poçtunuz göstərilmir.